lenalidomide,rituximab
Not Tagged
['bet', 'augment,trial', 'lenalidomide', 'ritux', ' lena', 'nhl', 'lymphoma', 'lymsm', 'imab ']
long-term follow-up from the augment trial by dr. (1 yr of r2 vs r-placebo) in r/r inhl demonstrates better os at 5.5 years of follow-up. in addition, time to next tx was sig. lower in r2 arm. great time-limited option! #ash22 #lymsm 
#lymsm & #mmsm hematologist & patient-reported outcomes researcher @CUHematology. Founder of https://t.co/kN6qeGXfg5, @inTrainingDoc & @inHouseMag. ??????